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Abstract The objective of this study was to investigate the
clinical pathological characteristics of breast cancer (BC) pa-
tients with secondary diabetes after systemic therapy without
preexisting diabetes. A total of 1434 BC patients received
systemic therapy and were analyzed retrospectively. Fasting
plasma glucose (FPG) levels were monitored prior to the treat-
ments, during the course of systemic therapy, and at the
follow-up visits. Cox regression models were used to estimate
the associations between the clinical pathological characteris-
tics of BC and the cause-specific hazard of developing sec-
ondary diabetes. Among the 1434 BC patients, 151 had
preexisting type 2 diabetes. Of the remaining 1283 patients
with normal FPG levels prior to the systemic therapy, 59 de-
veloped secondary diabetes and 72 displayed secondary im-
paired fasting glucose (IFG) over a mean follow-up of
41 months. The prevalence of secondary type 2 diabetes in
BC patients was 4.6% (59/1283), which was obviously higher
than that of the normal control group (1.4 %, P<0.001). The
percentage of older patients (P<0.05), menopausal patients
(P<0.001), and obese patients (P<0.01) tended to be lower
in the secondary diabetic group. In addition, these patients
with secondary diabetes had later pathological stages
(P<0.01), more lymph node metastasis (P<0.05), negative
estrogen receptor (ER) expression (P<0.05), and smaller size
of tumors (P<0.05). After adjusting for age and BMI, the risk
of developing secondary diabetes and IFG in subjects with
later pathological stage BC (hazard ratio (HR)=1.623; 95 %
confidence interval (CI) 1.128–2.335 (P<0.01)), negative
progesterone receptor (PR) expression (HR=0.530; 95 % CI
0.372–0.755 (P<0.001)), positive human epidermal growth
factor receptor 2 (HER2) expression (HR=1.822; 95 % CI
1.230–2.700 (P<0.01)), and more lymph node metastasis
(HR=1.595; 95 % CI 1.128–2.258 (P<0.01)) was significant-
ly higher. In conclusion, this study shows that an increase in
the incidence of diabetes among breast cancer survivors after
systemic therapy, especially the patients with later pathologi-
cal stages, more lymph node metastasis, negative hormone
receptor expression, and positive HER2 expression. Our study
suggests that greater diabetes screening and prevention strat-
egies among breast cancer patients after systemic treatment
are needed in China.
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Introduction
Breast cancer (BC) and diabetesmellitus are common diseases
and major health care problems among females in the world.
The overall prevalence of diagnosed diabetes was 11.6 %
among the Chinese adults, 12.1 % among men, and 11.0 %
among women [1]. Breast cancer accounted for 25.2 % of all
cancers and 14.7 % of cancer deaths in females worldwide in
2012 [2]. In China, breast cancer is currently the most
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common malignant tumor, and as a result, it is the second
leading cause of cancer deaths in women [3].
Many BC patients are also diagnosed with preexisting di-
abetes, possibly due to the shared etiology and signaling path-
ways [4, 5]. These include old age; obesity; genetic predispo-
sition; a sedentary lifestyle; metabolic syndrome; as well as
biological factors such as hyperinsulinemia, hyperglycemia,
and chronic inflammation [6–10]. Epidemiological studies
suggest that type 2 diabetes mellitus (T2DM) increases breast
cancer risk and thereafter goes with an increased mortality. A
study by Larsson et al. suggested that females with diabetes
had a 20 % increased risk of postmenopausal breast cancer.
Interestingly, the statistical association between diabetes and
breast cancer is significantly stronger in Asia than that in
North America [4]. Diabetes may influence therapy choices,
affect therapeutic toxicities, and cause worse outcomes. Fur-
ther studies suggested that diabetes was associated with a 40–
50% increased mortality in BC patients [7, 8]. In addition, the
risk of developing BC increased significantly after the long-
term use of insulin glargine [11].
On the other hand, emerging evidence suggests that fe-
males with BC have an increased risk of developing diabetes.
Lipscombe et al. reported that 9.7 % of older females with
early-stage BC developed diabetes after adjuvant therapy for
a median follow-up of 5.8 years. The risk started to increase
2 years after diagnosis, especially for the patients who re-
ceived adjuvant chemotherapy [12]. A recent population-
based retrospective study found that previously undiagnosed
diabetes was associated with advanced-stage cancer and in-
creased mortality [13]. However, no study has been reported
that whether secondary diabetes is associated with chemother-
apy in both young and older females with breast cancer and
how it is affected by clinical pathological characteristics.
In this study, we focused on the clinical pathological char-
acteristics of breast cancer patients with secondary diabetes
after systemic therapy without preexisting diabetes and tried
to provide the clinical guidance for these patients.
Subjects and methods
Subjects
With Ethics Committee approval, we retrospectively evaluat-
ed 1434 patients with BC aged 20–80 years who were treated
in Renmin Hospital of Wuhan University, Hubei Cancer Hos-
pital, and Union Hospital of Tongji Medical College, Wuhan,
China, between January 2008 and July 2014. All the patients
were diagnosed by pathological examination. The diagnosis
of type 2 diabetes mellitus was based on the following criteria:
the medical history and prescription records which were ob-
tained by doctors during interview and the definition of the
1999 World Health Organization (WHO), including a fasting
plasma glucose (FPG) ≥7.0 mmol/L, a random plasma glu-
cose ≥11.1 mmol/L, or a 2-h plasma glucose ≥11.1 mmol/L
during an oral glucose tolerance test (OGTT). Impaired fasting
glucose (IFG) was defined as values above normal, but below
the diagnostic cutoff for diabetes (≥6.1 to <7.0 mmol/L) [14].
All the patients accepted the following exclusion criteria: (1)
type 1 diabetes mellitus, (2) history of cancer, and (3) male
patient. Finally, all the patients included in our study had com-
plete data available and received systemic treatment including
surgery and chemotherapy.
Data collection
Both demographic information and medical records were col-
lected for analysis. The demographic information included
age at the time of breast cancer diagnosis, height, and weight.
The medical history recorded included a previous history of
diabetes, menopausal status, age of onset of menarche, family
history of breast cancer, stage of breast cancer at the time of
diagnosis, hormonal receptor status (estrogen, progesterone)
by immunohistochemistry (IHC) assay, human epidermal
growth factor receptor 2 (HER2)/neu status by either an IHC
assay or a fluorescence in situ hybridization (FISH) assay
(HER2-positive means FISH-amplified or IHC3+; HER2-
negative means FISH-non-amplified or IHC 0–1+; IHC2+ is
defined as borderline which requires FISH assay.), lymph
node status, surgical therapy, chemotherapeutic records, labo-
ratory results, recurrence of breast cancer, history of bilateral
breast cancer, and survival of the patients since the diagnosis
of cancer (in months). Death was validated using social secu-
rity records. Obesity (BMI ≥25 kg/m2) was diagnosed accord-
ing to the Asia-Pacific criteria [15]. Detailed information is
presented in Table 1.
Previously diagnosed diabetes among the breast cancer pa-
tients was determined on the self-report and the medical re-
cord. As part of routine clinical care, FPG levels were deter-
mined presurgery, before the commencement of each chemo-
therapy cycle, and at 3–6months intervals after the final cycle.
The management of diabetes (including dietary control, oral
drugs, or insulin) and the discontinuation of chemotherapy
were recorded. All the patients that were diagnosed with dia-
betes were referred to an endocrinologist. Cohort entry date
was defined as the date of breast cancer diagnosis.
Treatment
All BC patients received surgical treatment and chemothera-
py. In addition, most patients with diabetes were treated with
oral hypoglycemic agents or insulin. The systemic treatment
for BC was performed according to guidelines and standard
protocols. All BC patients received modified radical or sim-
plified mastectomy. Chemotherapy included anthracycline-
based combined chemotherapy, paclitaxel/docetaxel alone or
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combined with other drugs, and second-line chemotherapy
regimen (such as capecitabine, gemcitabine, platinums, and
vinorelbine). Adverse events (AE) were documented daily
during chemotherapy and were classified according to the
Common Terminology Criteria for Adverse Events (version
4.0) for final analysis [16]. Radiotherapy, endocrine therapy,
and HER2-targeted therapies were given following guidelines
and standard protocols.
Outcome and follow-up
Our primary outcome was a diagnosis of diabetes from cohort
entry date until July 2014. Diabetes was identified according
to the definition of the 1999 WHO [14]. Persons in the cohort
were followed until the incidence of diabetes, the recurrence
of breast cancer, the occurrence of a newmalignancy, death, or
the end of the follow-up period.
Statistical analysis
Data were stored in an Excel database by three research assis-
tants, and descriptive statistics were calculated for all the study
variables. The basic conditions and clinical pathological char-
acteristics of the patients were tested using the Χ2 test. The
median onset time of secondary diabetes was analyzed be-
tween each group using a Kaplan–Meier analysis, and the
significance test was performed using the log-rank test. The
Cox proportional hazard model was used to examine the cor-
relation between each clinical pathological characteristics and
the occurrence of secondary diabetes. The factors included in
the Cox multifactorial regression model were both statistical
and clinical factors, including age, menopausal status (post-
and premenopausal), pathology reports of the lymph nodes
(with and without lymph node metastasis), TNM stage (early
and advanced stage), expression of estrogen receptor (ER;
positive and negative), expression of progesterone receptor
(PR; positive and negative), and expression of HER2 (posi-
tive, negative, and borderline). Statistical analysis was per-
formed using SPSS (version 17.0). All tests of statistical sig-
nificance were based on a two-sided P<0.05.
Results
Increased incidence of BC patients with secondary
diabetes following systemic therapy
The median follow-up time for this study was 41 months (16–
66 months). A total of 1434 BC patients treated with system-
atic therapy with available FPG data were included in the
study. Of these, 10.5 % (151/1434) had preexisting diabetes.
The FPG was measured with the remaining 1283 patients
without preexisting diabetes during each chemotherapy cycle
and at 3–6 months intervals after the final cycle, based on the
available data and follow-up results. There were 89.8 %
(1152/1283) of the patients with normal FPG levels through-
out the whole study period. Approximately 10.2% (131/1283)
of the patients developed hyperglycemia during systemic
Table 1 General characteristics











Age (years), mean±SD 54.43±8.97 54.90±9.35 51.07±9.62 0.021
Urban/rural status
Urban 98 (64.90 %) 44 (74.58 %) 48 (66.67 %) 0.401
Rural 53 (35.10 %) 15 (25.42 %) 24 (33.33 %)
Family history of BC in first degree relatives
Positive 7 (4.64 %) 1 (1.70 %) 1 (1.39 %) 0.332
Negative 144 (95.36 %) 58 (98.30 %) 71 (98.61 %)
Age of onset of menarche (years), mean±SD 13.82±1.45 13.08±1.32 12.73±1.33 <0.001
Menopause status
Premenopausal 49 (32.45 %) 17 (28.81 %) 35 (48.61 %) <0.001
Postmenopausal 102 (67.55 %) 42 (71.19 %) 37 (51.39 %)
Age at first live birth (years)
20–29 140 (92.72 %) 53 (89.83 %) 65 (90.28 %) 0.728
≥30 11 (7.28 %) 6 (10.17 %) 7 (9.72 %)
Breastfeeding (months)
0–6 15 (9.93 %) 6 (10.17 %) 9 (12.50 %)
≥7 136 (90.07 %) 53 (89.83 %) 63 (87.50 %) 0.837
BMI (kg/m2), mean±SD 24.86±2.44 23.92±1.59 23.19±1.31 <0.01
Data are expressed as means±SD or n (%)
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therapy, including 5.6 % (72/1283) with secondary IFG and
4.6 % (59/1283) with secondary diabetes. Detailed informa-
tion describing these three groups is summarized in Fig. 1.
In addition, 1361 females without BC or preexisting type 2
diabetes who received an annual routine physical examination
at RenminHospital ofWuhanUniversity were followed up for
3 year as the normal control group. Of these, 3 % (41/1361)
developed hyperglycemia, including 1.6 % (22/1361) with
IFG and 1.4 % (19/1361) with diabetes. These percentages
were significantly lower than those of BC patients (P<0.001).
Clinical pathological characteristics of BC patients
with secondary diabetes and IFG
The clinical pathological characteristics of the secondary dia-
betic group and control groups are summarized in Table 1.
The mean age of patients with preexisting diabetes was
54.43±8.97 years, which was older than that of the secondary
IFG BC group (51.07±9.62 years, P<0.05). The mean age of
patients with normal FPG during the follow-up was 43.33±
3.59 years, which was younger than that of the other groups
(P<0.001). Among the BC patients with preexisting diabetes,
the percentage of postmenopausal patients was 67.55 %,
which was significantly higher than that of the groups with
secondary IFG and diabetes (P<0.001), while the percentage
of postmenopausal patients was 42.62 % among the BC pa-
tients with normal FPG during the follow-up, which was sig-
nificantly lower than the other groups (P<0.001). The mean
age of onset of menarche in the secondary IFG BC patients
was significantly younger than that of the other two groups
(P<0.001). BMI of patients with preexisting diabetes was
significantly higher than that of the other groups (P<0.01).
There were no significant differences in urban/rural habita-
tion, family history of BC in first degree relatives, and age at
first live birth and breastfeeding.
Of the patients who developed secondary diabetes, 52.5 %
(31/59) were diagnosed initially with advanced-stage BC
(stages III/IV), while 31.1 % (47/151) of patients with
preexisting diabetes were diagnosed initially with advanced
BC. The results show that the percentage of advanced-stage
BC was higher in the secondary diabetes group (Table 2,
P<0.01). In the secondary diabetes group, patients tend to
have more lymph node metastasis than the other two groups
(P<0.05). In addition, patients with preexisting diabetes had
larger average tumor sizes than the patients with secondary
diabetes and secondary IFG (P<0.05). Meanwhile, in the sec-
ondary diabetes group, patients tended to have higher percent-
ages of negative ER expression than the other two groups
(P<0.05). There were no significant differences in other indi-
cators among these groups (Table 2).
Risk analysis for BC patients with secondary diabetes
and IFG
A total of 59 patients developed secondary diabetes during a
median follow-up of 41 months. Meanwhile, 72 patients de-
veloped secondary IFG, a status of prediabetes, which was
also associated with an increased risk of cancer [17]. All fac-
tors for each group were included in the Kaplan–Meier anal-
ysis, and there were significant differences in clinicopatholog-
ical features including menopausal status (P=0.003); patho-
logical stages (P<0.001); lymph node status (P=0.009); and
Fig. 1 Patient flow diagram
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expression of PR, ER, and HER2 (P=0.004, 0.599, and 0.001,
respectively) (Fig. 2). Table 3 shows descriptives for the con-
ditional probability of developing diabetes over time in pa-
tients with BC treated with comprehensive therapy after
adjustment for age and BMI. The risk of developing sec-
ondary diabetes for subjects with advanced BC (hazard
ratio (HR)=1.623; 95 % confidence interval (CI) 1.128–
2.335 (P<0.01)) was higher than for those with early BC.
Although the risk of developing secondary diabetes for
patients with negative PR expression (HR=0.530; 95 %
CI 0.372–0.755 (P<0.001)) was higher than for those with
positive PR expression, the risk of developing secondary
diabetes for patients with negative ER expression was
slightly higher than for those with positive ER expression
(HR=0.806; 95 % CI 0.566–1.146 (P=0.230)), which was
not statistically significant. Furthermore, the risk of devel-
oping secondary diabetes for the patients with positive
HER2 expression (HR=1.822; 95 % CI 1.230–2.700
(P<0.01)) was higher than for those with negative HER2
expression. The risk of developing secondary diabetes for
subjects with lymph node metastasis (HR=1.595; 95 % CI
1.128–2.258 (P<0.01)) was higher than for those without
lymph node metastasis. Menopausal status did not signif-
icantly modulate systemic therapy–diabetes risk associa-
tion. Therefore, pathological stages, lymph node metastasis
status, hormone receptor expression, and HER2 expression
were independent risk factors for developing secondary
diabetes for the BC patients after systemic therapy.
Table 2 Clinical pathological
characteristics and follow-up of
breast cancer patients with












I 35 (23.18 %) 10 (16.95 %) 16 (22.22 %)
II 69 (45.70 %) 18 (30.51 %) 35 (48.61 %)
III 45 (29.80 %) 31 (52.54 %) 19 (26.39 %)
IV 2 (1.32 %) 0 2 (2.78 %)
Tumor 0.048
T1 39 (25.83 %) 15 (25.42 %) 26 (36.11 %)
T2 90 (59.60 %) 26 (44.07 %) 38 (52.78 %)
T3 14 (9.27 %) 17 (28.81 %) 8 (11.11 %)
T4 8 (5.30 %) 1 (1.70 %) 0
Lymph node 0.041
N0 75 (49.67 %) 23 (38.98 %) 34 (47.22 %)
N1 37 (24.50 %) 6 (10.17 %) 20 (27.78 %)
N2 18 (11.92 %) 13 (22.03 %) 5 (6.94 %)
N3 21 (13.91 %) 17 (28.82 %) 13 (18.06 %)
Metastasis (at diagnosis) 0.467
M0 148 (98.01 %) 59 (100 %) 70 (97.22 %)
M1 3 (1.99 %) 0 2 (2.78 %)
Stage (at diagnosis) 0.007
Early 104 (68.87 %) 28 (47.46 %) 51 (70.83 %)
Advanced 47 (31.13 %) 31 (52.54 %) 21 (29.17 %)
Hormone receptor
ER positive 108 (71.52 %) 37 (62.71 %) 38 (52.78 %) 0.022
ER negative 43 (28.48 %) 22 (37.29 %) 34 (47.22 %)
PR positive 84 (55.63 %) 33 (55.93 %) 32 (44.44 %) 0.255
PR negative 67 (44.37 %) 26 (44.07 %) 40 (55.56 %)
HER2
Positive 41 (27.15 %) 17 (28.81 %) 23 (31.94 %) 0.333
Negative 96 (63.58 %) 32 (54.24 %) 48 (66.67 %)
Borderline 14 (9.27 %) 10 (16.95 %) 1 (1.39 %)
Recurrence <0.001
No 134 (88.74 %) 48 (81.36 %) 59 (81.94 %)
Yes 17 (11.26 %) 11 (18.64 %) 13 (18.06 %)
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Follow-up and clinical outcome
Complete follow-up information was collected from all the
patients in this study. The median follow-up was 41 months
(16–66). Of the 59 patients with preexisting diabetes, 94.7 %
(54/59) received anti-diabetes therapy and 8.5 % (5/59) recov-
ered to normal FPG levels after using diet and exercise. Two
patients discontinued chemotherapy due to severe diabetes-
related adverse effects. Overall, 189 patients died during the
observation period; 7.95 % (12/151) of those with preexisting
Fig. 2 The risk rate for secondary diabetes and IFG in breast cancer
patients with ER-positive group and ER-negative group. a The risk rate
for secondary diabetes and IFG in breast cancer patients with PR-positive
group and PR-negative group. b The risk rate for secondary diabetes and
IFG in breast cancer patients with HER2 positive group and HER2
negative group. c The risk rate for secondary diabetes and IFG in breast
cancer patients with premenopausal group and postmenopausal group. d
The risk rate for secondary diabetes and IFG in breast cancer patients with
sentinel lymph node metastasis group and without sentinel lymph node
metastasis group. e The risk rate for secondary diabetes and IFG in breast
cancer patients with early stage group and advanced stage group
Table 3 Median onset time and
95 % confidence intervals for
secondary diabetes and IFG after
systemic therapy for breast cancer
patients
Median onset time (months, 95 % CI) P values P values (adjusted
for age and BMI)
TNM stages
Early 65.667 (62.867, 68.468) 0.000 0.009
Advanced 54.880 (47.667, 62.093)
Menopausal status
Premenopausal 66.111 (62.678, 69.543) 0.003 0.111
Postmenopausal 61.736 (56.208,67.265)
ER
Negative 64.153 (59.576, 68.730) 0.599 0.230
Positive 67.551 (61.036, 74.066)
PR
Negative 58.921 (54.263, 63.578) 0.004 0.000
Positive 71.312 (65.877, 76.746)
HER2
Negative 67.085 (64.212, 69.958) 0.001 0.003
Positive 59.677 (51.666, 67.688)
Lymph nodes
Negative 74.828 (70.826, 78.830) 0.009 0.008
Positive 60.264 (75.368, 86.632)
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diabetes, 13.56 % (8/59) of those with secondary diabetes,
14.1 % (162/1152) of those with normal FPG, and 9.72 %
(7/72) of those with secondary IFG (P=0.070). The recur-
rence percentage of BC patients is significantly higher in the
secondary diabetes group (P<0.05, Table 2). Three patients
with secondary diabetes developed bilateral primary breast
cancer, compared with two patients in the preexisting diabetes
group. One secondary diabetes patient developed squamous
cell lung cancer, and one preexisting diabetes patient devel-
oped ovarian cancer.
Discussion
BC and type 2 diabetes share similar etiologies, including
hyperinsulinemia, hyperglycemia, and chronic inflammation
[18]. Previous studies showed that both insulin resistance and
diabetes positively affect cancer incidence [19–22]. However,
the effect of BC and the use of systemic therapies for BC on
the development of diabetes remains unclear [13]. In this
study, we retrospectively investigated the potential association
between systemic therapy and the incidence of type 2 diabetes
in Chinese females with BC. A total of 1434 BC patients were
followed up for a mean period of 41 months. Data revealed
that the risk of developing diabetes after systemic therapy for
the BC patients was higher than that for the normal control
group (1.4 %), suggesting the potential association between
systemic therapy and secondary diabetes in Chinese patients
with BC. This increased incidence of secondary diabetes was
associated with advanced BC stage at initial diagnosis.
A recent investigation revealed that the prevalences of di-
abetes and prediabetes in Chinese adults, 20 years of age or
older, were 9.7 % (10.6 % among men and 8.8 % among
women) and 15.5 % (16.1 % among men and 14.9 % among
women), respectively [23]. A study in Canada reported that
16.5 % (1011/6107) of women with breast cancer aged 55–79
were diagnosed with diabetes at diagnosis, which is higher
than the prevalence of 10.5 % (151/1434) in our study [7].
This suggests that the level of economic development and
different lifestyles and diets may affect the prevalence of dia-
betes in different populations. However, patients’ age and the
tendency for obesity were both considered to be risk factors
for diabetes [7].
Recently, Ji et al. investigated the incidence of diabetes and
prediabetes in 119 Chinese female adult BC patients after
systemic treatment and found prevalences of 21.8 and
43.7 %, respectively [24]. Although these observations sup-
port our finding that patients with BC after systemic therapy
tended to develop secondary diabetes, the increased incidence
of diabetes was higher than in the current study. There are
several possible reasons for this discrepancy. Firstly, they
measured 2 h plasma glucose levels through OGTT, which
were increased in 80.0 % of patients with normal FPG levels.
Secondly, they investigated only 119 BC patients, which was
not a large cohort of breast cancer survivors. Finally, the mean
follow-up duration was only 18 months in the study.
Similar to previous studies [25], our results indicated that
breast cancer patients with preexisting diabetes tended to have
a high percentage of older, menopausal, and obese patients. In
addition, breast cancer patients with diabetes were more likely
to have larger tumor size, later pathological stages, a higher
rate of lymph node metastasis, and a higher rate of ER-
negative expression, which was also consistent with the find-
ings of Hou et al. [25]. In our study, later pathological stages
and more lymph node metastasis in the diabetic breast cancer
group indicate that hyperinsulinemia promotes tumor cell pro-
liferation and metastasis to some extent, which may be asso-
ciated with interaction between insulin and its receptor, which
may active the PI3K and Ras–MAPK pathways. Therefore,
this study supports the hypothesis that diabetes is a high-risk
factor affecting the growth of breast tumors and axillary
lymph node metastasis. Therefore, systemic treatments for
the breast cancer patients with diabetes have to be tailored to
the individual, and strict control of blood sugar level is abso-
lutely important.
Furthermore, our study suggests that secondary diabetes
was associated with later pathological stages, more lymph
node metastasis, and higher incidence of distance recurrence.
The risk of developing abnormal plasma glucose levels after
systemic therapy was significantly higher in patients with ad-
vanced stages than in patients with early stages. Patients with
secondary diabetes were associated with a significantly higher
risk of distance metastasis than patients with preexisting dia-
betes. One possible explanation for this is that hyperglycemia,
hyperinsulinemia, and inflammation occur in newly diag-
nosed diabetes, which can result in tumor cell proliferation
and metastasis [26–30]. However, hyperglycemia and
hyperinsulinemia may exist rarely in patients with preexisting
diabetes because blood glucose levels are usually controlled
well using oral hypoglycemic agents or insulin. Nevertheless,
because we did not have detailed information regarding insu-
lin and glucose levels or the dose of oral hypoglycemic agents
or insulin, further experiments are needed to be carried out to
understand the underlying mechanism.
Very limited literature is currently available regarding the
risk of secondary diabetes among breast cancer survivors. A
study [12] provides evidence for an increased incidence of
diabetes among postmenopausal breast cancer survivors, at
age 55 or older, especially for patients who received adjuvant
chemotherapy. Our results indicated that breast cancer patients
with later pathological stages, more lymph node metastasis,
negative hormone receptor expression, and positive HER2
expression tended to have a higher percentage of risk to de-
velop secondary diabetes and IFG. Actually, the BC patients
with the above clinical pathological characteristics, which are
associated with poor prognosis, may receive more cycles of
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standard chemotherapy in the current study, which may con-
tribute to the increased incidence of developing secondary
type 2 diabetes. This study supports the hypothesis that BC
patients after adjuvant chemotherapy experienced a higher
rate of diabetes, at least in part, which is consistent with results
of the previous study [12]. This conclusion is supported by a
number of recent observations. First, Feng et al. reported that
5-FU-based chemotherapy might affect beta cell function by
causing acute beta cell damage at the early phase and chronic
damage at the later phase [31]. Second, other types of chemo-
therapy agents such as vinblastine and taxanes, which target
microtubules and microfilaments, may inhibit the release of
insulin and then increase blood sugar levels [32]. In addition,
glucocorticoids are used commonly to reduce allergic or gas-
trointestinal adverse reactions during chemotherapy, which
may cause temporary hyperglycemia [33–37]. Furthermore,
the weight gain caused by high-energy diet and estrogen sup-
pression during chemotherapy may further promote diabetes
[38–40]. Finally, the impaired hepatic and renal functions
caused by chemotherapy were suggested to be risk factors
for the development of diabetes [41]. Nevertheless, the lack
of a control group of BC patients without chemotherapy in our
study means that the precise mechanism for our findings is
unclear, and so further studies using an additional control co-
hort are needed to explore this relationship.
Nonetheless, our study has some limitations. It is important
to note that the current study may be affected by the limited
sample size (1434 cases) from three centers in one area. An
additional national multicenter trial is needed to achieve a
definitive conclusion regarding the effect of adjuvant therapy
for BC patients on the incidence of secondary diabetes. It was
reported that secondary diabetes was associated with signifi-
cantly increased mortality [4]; however, we did not observe
this association. This may be due to the different follow-up
times, as the relative risk of diabetes for BC patients may
increase over time [14]. In addition, we also did not have
information regarding the use of prescription drugs, the doses
of chemotherapy agents (such as vinblastine, taxanes, or glu-
cocorticoids), or the dose of endocrine therapies such as ta-
moxifen, which was associated with an increased risk of dia-
betes among older females [42–45].
In summary, this large population-based study shows an
increase in the incidence of diabetes among breast cancer
survivors after systemic therapy, especially the patients
with later pathological stages, more lymph node metasta-
sis, negative hormone receptor expression, and positive
HER2 expression. It is possible that chemotherapy is a
factor leading to the increased risk of diabetes among
the patients receiving systemic treatment. The reasons for
this relationship are uncertain, and further research is nec-
essary. In the meantime, greater diabetes screening and
prevention strategies among breast cancer patients after
systemic treatment are needed in China.
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